MAPT and Alzheimer disease: However, given the absence of differences in plasma AD biomarkers between groups, it could be hypothesized that the effects of the MLI+EGCG on cognition are not exerted via amyloid and/or tau pathways in the one-year intervention period but rather though other modifiable risk factors for dementia, not specific to AD.